← All trials

Adding Ruxolitinib to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

Official title: Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

The short version

This study is testing whether adding a drug called ruxolitinib to usual treatment helps people with newly diagnosed glioblastomaglioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary.

Read our full plain-language summary

What the trial team says

The purpose of this research is to test the safety and effectiveness of the investigational drug ruxolitinib when it is combined with standard of care treatment (radiation therapy and temozolomide) for the treatment of newly diagnosed glioblastoma. Half the people in the study will be assigned to take the study drug ruxolitinib in addition to the standard of care temozolomide and radiation therapy and the other half will be assigned to the standard of care temozolomide and radiation therapy only. This assignment will be randomized in a 1-to-1 ratio, like the flip of a coin.

Key facts

Registry number

NCT06991101

Stage of testing

Phase 2

Conditions studied

Glioblastoma, Brain Cancer, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma

Where it is running

This trial lists 2 sites.

• Florida
  • Baptist Health Herbert Wertheim Cancer Institute (Miami)
• New York
  • New York University Langone's Perlmutter Cancer Institute (New York)

This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.